



# Substance Use Disorder (SUD) & Psychedelics


180+ clinical studies and trials

## Emmes' Experience In Psychedelic Research Is Paving The Way For Breakthrough Therapies

With extensive global experience in conducting research across diverse indications—including substance use disorders, Alzheimer's disease, traumatic brain injury, neuromuscular conditions, and epilepsy—Emmes brings a proven track record of excellence. Backed by over 15 years of partnerships with leading agencies such as NINDS, NIMH, and NIDA, we are committed to advancing scientific discovery. Our expertise includes supporting rigorous, multi-site psychedelic clinical research and contributing to groundbreaking work, such as the validation of a novel neuromuscular outcome measure within the FDA's COA Qualification Program.

## Key Programs and Clinical Trials in SUD & Psychedelics

NIDA Clinical Trials Network  
Clinical Coordinating Center and  
Data/ Statistics Center



Multi-site Randomized  
Controlled Trial of Psilocybin  
for Major Depressive Disorder



# Psychedelic Research Highlights

Emmes has provided support for rigorous multi-site psychedelic trials since 2017 in major depressive disorder, alcohol use disorder, migraine, and rare headache disorders.


Emmes' successful delivery of a large multi-site, randomized, double-blind Phase 2 clinical trial led to positive clinical trial results published in JAMA featuring 3 Emmes co-authors –

## Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial

“The data suggest a benefit which is truly encouraging. As the largest and most rigorous study conducted across a wide spectrum of individuals with major depressive disorder, the results show promise for all people struggling with this condition.” – Charles Raison, MD

# SUD Research Highlights

## Substance Use Disorder: Emmes Supports NIDA Clinical Trials Network As The Clinical Coordinating Center



## Data and Statistics Center

01

Expertise in electronic data capture and analysis uniquely designed for substance use disorder (SUD) population, including Timeline Followback for self-reported substance use (Oden et al., 2011) and ePRO mobile surveys.



02

Methodological expertise including alternative approaches to study design and missing data, as well as simulation studies for sample size calculations (Sharma et al., 2015).



03

Subject matter expertise across SUDs and comorbid mental health conditions; assistance with assessment selection and implementation for biomedical and behavioral research studies.



04

Experience and leadership in the development and maintenance of Common Data Elements and data harmonization (Ghitza et al., 2013, 2015; Karnik et al., 2021, 2022).



For additional information on our Neuroscienceservices, please visit [www.emmes.com](http://www.emmes.com)